Published in J Clin Microbiol on August 01, 1986
Current perspectives on ophthalmic mycoses. Clin Microbiol Rev (2003) 3.18
Melanized fungi in human disease. Clin Microbiol Rev (2010) 2.89
Developments in fungal taxonomy. Clin Microbiol Rev (1999) 2.39
Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med (2012) 2.16
Scedosporium inflatum, an emerging pathogen. J Clin Microbiol (1988) 1.54
Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum. Antimicrob Agents Chemother (2012) 1.51
Exserohilum: an emerging human pathogen. Eur J Clin Microbiol Infect Dis (2006) 1.45
Detection of fungal DNA in human body fluids and tissues during a multistate outbreak of fungal meningitis and other infections. Eukaryot Cell (2013) 1.30
Novel Curvularia species from clinical specimens. Persoonia (2014) 1.15
Phaeohyphomycosis of the nasal sinuses caused by a new species of Exserohilum. J Clin Microbiol (1986) 1.10
Diversity of Bipolaris species in clinical samples in the United States and their antifungal susceptibility profiles. J Clin Microbiol (2012) 1.07
Phialophora repens, an emerging agent of subcutaneous phaeohyphomycosis in humans. J Clin Microbiol (1989) 1.06
Exserohilum infections associated with contaminated steroid injections: a clinicopathologic review of 40 cases. Am J Pathol (2013) 1.03
Whole-genome analysis of Exserohilum rostratum from an outbreak of fungal meningitis and other infections. J Clin Microbiol (2014) 0.93
Maxillary sinusitis caused by Pleurophomopsis lignicola. J Clin Microbiol (1997) 0.91
Hospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia. Can J Infect Dis Med Microbiol (2007) 0.88
Bipolaris spicifera causes fungus balls of the sinuses and triggers polypoid chronic rhinosinusitis in an immunocompetent patient. J Clin Microbiol (2003) 0.88
Diagnosing fungal infections in immunocompromised hosts. J Clin Pathol (1992) 0.86
History of medical mycology in the united states. Clin Microbiol Rev (1996) 0.78
Invasive rhinosinusitis by Exserohilum rostratum in an immunocompetent child. BMJ Case Rep (2014) 0.76
Phaeohyphomycotic cyst caused by a recently described species, Phaeoannellomyces elegans. J Clin Microbiol (1987) 0.75
Exogenous Helminthosporium endophthalmitis. Br J Ophthalmol (1994) 0.75
Differentiation of medically important isolates of Bipolaris and Exserohilum with exoantigens. J Clin Microbiol (1990) 0.75
Extensive Exserohilum infection in a burn patient. JAAD Case Rep (2015) 0.75
Mycotic keratitis caused by concurrent infections of Exserohilum mcginnisii and Candida parapsilosis. BMC Ophthalmol (2013) 0.75
Isolation of a Nodulisporium species from a case of cerebral phaeohyphomycosis. J Clin Microbiol (2001) 0.75
Recurrent phaeohyphomycosis: a case report. J Clin Diagn Res (2013) 0.75
Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol (1983) 2.84
Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med (1983) 2.45
Allergic bronchopulmonary disease caused by Curvularia lunata and Drechslera hawaiiensis. Thorax (1981) 1.79
Phaeohyphomycosis caused by Drechslera spicifera in a cat. J Am Vet Med Assoc (1975) 1.69
Infections caused by Drechslera species: case report and review of the literature. Rev Infect Dis (1985) 1.32
Dematiaceous fungal keratitis. Clinical isolates and management. Br J Ophthalmol (1975) 1.32
Bronchopulmonary helminthosporiosis. Am J Clin Pathol (1970) 1.26
Drechslera hawaiiensis: causative agent of a fatal fungal meningo-encephalitis. Sabouraudia (1973) 1.20
Phaeohyphomycosis of the nasal sinuses caused by a new species of Exserohilum. J Clin Microbiol (1986) 1.10
Equine phaeohyphomycosis caused by Drechslera spicifera. Can Vet J (1975) 1.09
Phaeohyphomycosis of brain: granulomatous encephalitis caused by Drechslera spicifera. Am J Clin Pathol (1982) 1.05
Fungal peritonitis: complication of continuous ambulatory peritoneal dialysis. Med J Aust (1981) 0.91
[First human case of Drechslera longirostrata mycosis. Spondylodiscitis complicating prosthesis endocarditis. Treatment with combined ketoconazole and amphotericin B]. Nouv Presse Med (1982) 0.89
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol (1983) 10.49
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol (1988) 8.67
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
A waterborne outbreak of cryptosporidiosis in normal hosts. Ann Intern Med (1985) 5.27
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am (1993) 3.55
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40
Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol (1983) 2.84
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Evaluation of YeastIdent and Uni-Yeast-Tek yeast identification systems. J Clin Microbiol (1987) 2.74
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol (1995) 2.66
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Mycoses caused by Candida lusitaniae. Rev Infect Dis (1988) 2.53
Storage of stock cultures of filamentous fungi, yeasts, and some aerobic actinomycetes in sterile distilled water. Appl Microbiol (1974) 2.50
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Evaluation of the updated Vitek yeast identification data base. J Clin Microbiol (1990) 2.45
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Recent taxonomic developments and changes in medical mycology. Annu Rev Microbiol (1980) 2.25
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol (2005) 2.18
Invasive aspergillosis. Rev Infect Dis (1984) 2.18
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother (2000) 2.13
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Fluconazole-resistant Candida albicans. Clin Infect Dis (1993) 2.10
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis (1998) 2.03
Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol (2009) 2.02
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.99
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother (1989) 1.89
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagn Microbiol Infect Dis (1994) 1.88
Lacazia loboi gen. nov., comb. nov., the etiologic agent of lobomycosis. J Clin Microbiol (1999) 1.86
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Evaluation of the Baxter-MicroScan 4-hour enzyme-based yeast identification system. J Clin Microbiol (1991) 1.76
Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol (1998) 1.72
Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. J Antimicrob Chemother (1995) 1.72
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol (1999) 1.71
Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses (1994) 1.69
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Nutritional physiology and taxonomy of human-pathogenic Cladosporium-Xylohypha species. J Med Vet Mycol (1996) 1.67
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis (1998) 1.66
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1999) 1.62
Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol (1996) 1.61
In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother (2000) 1.59
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med (2000) 1.58
Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol (2007) 1.58
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
Ocular penetration and pharmacokinetics of topical fluconazole. Cornea (1997) 1.56
Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol (1998) 1.55
Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant (2006) 1.55
Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol (2007) 1.55
Scedosporium inflatum, an emerging pathogen. J Clin Microbiol (1988) 1.54
Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Arch Pathol Lab Med (1997) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Preparation of temporary or permanent mounts of microfungi with undisturbed conidia. Mycologia (1974) 1.51
Detection of fungi in cerebrospinal fluid. Am J Med (1983) 1.48
Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother (2000) 1.48
Maxillary sinusitis from Pseudallescheria boydii. Efficacy of surgical therapy. Arch Otolaryngol (1983) 1.48
Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis (1994) 1.46